Corrigendum to “P-137: ITHACA, A Randomized Multicenter Phase 3 Study of Isatuximab in Combination With Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Safety Run-in Preliminary Results” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S109- S110] (Clinical Lymphoma, Myeloma and Leukemia (2021) 21(S2) (S1–S189), (S2152265021X00122))

1. Ghobrial, I.M.
2. Rodríguez-Otero, P.
3. Koh, Y.
4. Martínez-López, J.
5. Parmar, G.
6. Prince, M.
7. Quach, H.
8. de la Rubia, J.
9. Hermansen, E.
10. Hungria, V.
11. Kalayoglu Besisik, S.
12. Kim, J.S.
13. Leleu, X.
14. Peceliunas, V.
15. Schjesvold, F.
16. Dubin, F.
17. Devisme, C.
18. Lepine, L.
19. Macé, S.
20. Oprea, C.
21. Mateos, M.-V.